Supernus Pharmaceuticals, Inc. Income Statement
SUPN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Supernus Pharmaceuticals, Inc. reported $719M in revenue and $39M in net loss for FY2025. Revenue has grown at a 62.5% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $85.5M | $215.0M | $147.5M | $92.7M | $147.5M | $92.7M | $12.0M | $1.5M | $803.0K |
| Cost of Revenue | $74.6M | $77.9M | $83.8M | $87.2M | - | $52.5M | $16.7M | $12.0M | $8.4M | $5.8M | $8.4M | $5.8M | $1.1M | - | - |
| SG&A Expense | $485.6M | $321.6M | $336.4M | $377.2M | $304.8M | $200.7M | $153.2M | $106.0M | $89.1M | $72.6M | $89.1M | $72.6M | $55.6M | $20.1M | $7.9M |
| R&D Expense | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M | $76.0M | $69.1M | $42.8M | $29.1M | $19.6M | $29.1M | $19.6M | $17.2M | $23.5M | $30.6M |
| Operating Income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $54.2M | $20.8M | -$5.3M | $20.8M | -$5.3M | -$61.9M | -$42.2M | -$37.8M |
| Interest Expense | $0 | $0 | $1.3M | $2.5M | $19.7M | $19.4M | $18.2M | $543.0K | $1.2M | $5.0M | $1.2M | $5.0M | $7.8M | $3.6M | $1.9M |
| Income Tax | -$10.5M | $24.0M | $1.5M | $32.0K | $19.8M | $41.7M | $34.4M | -$40.9M | $666.0K | $630.0K | $666.0K | $630.0K | $0 | $0 | -$16.2M |
| Net Income | -$38.5M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $91.2M | $13.9M | -$10.9M | $13.9M | -$10.9M | -$92.3M | -$46.3M | $53.8M |
| EPS (Basic) | $0.02 | $1.13 | $0.02 | $2.41 | $2.16 | $2.13 | $1.13 | $1.84 | $0.29 | -$0.26 | -$2.90 | -$2.72 | - | - | - |
| EPS (Diluted) | $0.02 | $1.04 | $0.02 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 | $0.28 | -$0.26 | -$2.90 | -$2.72 | $31.39 | -$26.38 | - |
| Shares Outstanding | 55.7M | 54.7M | 55.5M | 53.3M | 52.9M | 52.5M | 52.3M | 51.3M | 50.0M | 49.0M | 43.0M | 40.0M | 30.6M | 1.7M | 1.6M |
| Operating Margin | -8.7% | 12.3% | -0.9% | 6.9% | 14.8% | 33.4% | 173.8% | 25.2% | 14.1% | -5.7% | 14.1% | -5.7% | -515.2% | -2849.3% | - |
| Profit Margin | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 132.3% | 42.4% | 9.5% | -11.8% | 9.5% | -11.8% | -767.7% | -3127.3% | - |